| HOME >> BIOLOGY >> TECHNOLOGY |
ROCKVILLE, Md., Jan. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its aurora kinase/angiogenesis inhibitor, ENMD-2076.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
ENMD-2076 is a novel, dual-acting, kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular effects.
Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medical
Officer commented on the IND, "Acceptance of the Investigational New Drug
application for ENMD-2076 initiates the clinical program for our first
compound that targets kinases. This is an exciting class of compounds with
several recently approved in oncology indications. ENMD-2076 is unique in
class because it not only inhibits Aurora A selectively over Aurora B, it
also inhibits a number of other kinases important in the growth of tumors
and, in particular, growth factor receptors critical to angiogenesis.
ENMD-2076 has potent antitumor activity
'/>"/>
| SOURCE EntreMed, Inc. Copyright©2008 PR Newswire. All rights reserved |